Most medicines used worldwide are off-patent products – generic or biosimilar versions of branded medicines offering the same quality, safety, and efficacy at a lower price. They are the ‘silent ...
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...
TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...